Efficacy of aprepitant for CHOP chemotherapy-induced nausea,vomiting, and anorexia |
| |
| Affiliation: | 1. Center for Integrative Physiology, Division of Integrative Physiology, Kansai Electric Power Medical Research Institute, Kobe 650-0047, Japan;2. Division of System Neuroscience, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan;3. Division of Integrative Physiology, Department of Physiology, Jichi Medical University School of Medicine, Tochigi 320-0498, Japan;4. Pharmacological Department of Herbal Medicine, Kagoshima University Graduate School of Medical & Dental Sciences, Kagoshima 890-8544, Japan;5. Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh 2202, Bangladesh;1. Gastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan;2. Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan;3. Department of Medical Oncology, Osaki Citizen Hospital, Miyagi, Japan;4. Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Hokkaido, Japan;5. Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan;6. Department of Medical Oncology, Tohoku University Hospital, Miyagi, Japan;7. Comprehensive Cancer Center, Aizawa Hospital, Nagano, Japan;8. Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan;9. Clinical Oncology, Japanese Red Cross Ishinomaki Hospital, Miyagi, Japan;10. Division of Medical Oncology, Showa University Northern Yokohama Hospital, Kanagawa, Japan;11. Department of Gastroenterological Oncology, Hyogo Cancer Center, Hyogo, Japan;12. Department of Internal Medicine, Kushiro Rosai Hospital, Hokkaido, Japan;13. Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan;14. Department of Surgery, Kouseiren Takaoka Hospital, Toyama, Japan;15. Department of Internal Medicine, Showa University Koto Toyosu Hospital, Tokyo, Japan;16. Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Aomori, Japan;17. Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan;18. Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Hokkaido, Japan |
| |
| Abstract: | The objective of this study was to evaluate whether aprepitant in addition to 5-HT3 receptor antagonist is useful for preventing chemotherapy-induced nausea and vomiting (CINV) and anorexia in patients receiving CHOP therapy, and to evaluate the relationship between in vivo kinetics of plasma substance P and these adverse events. Patients with malignant lymphoma who received CHOP chemotherapy or THP (THP-ADR)-COP therapy were investigated for CINV and anorexia for 5 days after the start of chemotherapy. With the first course of chemotherapy, all patients received only granisetron on day1 as an antiemetic. Patients who experienced nausea, vomiting, or anorexia exceeding grade 1 in the first course received aprepitant for 3 days in addition to granisetron with the second course of CHOP chemotherapy. Plasma substance P concentrations at 24 and 72 hours after chemotherapy were measured. Nineteen patients were evaluated. Nausea, vomiting, or anorexia was observed with the first course in 7 of 19 patients. During the second course with aprepitant, no patients experienced vomiting, and the toxicity grade of nausea, vomiting, or anorexia was decreased compared with those in the first course. Substance P concentrations showed no differences after chemotherapy, in patients with nausea, vomiting, or anorexia and in patients without. The addition of aprepitant to 5-HT3 receptor antagonist appears effective for CINV or anorexia for patients who received CHOP chemotherapy. |
| |
| Keywords: | Aprepitant CHOP chemotherapy CINV Substance P Malignant lymphoma |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
